Lumera, Harvard Medical School to collaborate on protein biochip

Jan. 12, 2006 — Lumera Corp. (NASDAQ: LMRA), a Bothell, Wash., nanotechnology company, announced that it has entered into a collaborative agreement with Harvard Medical School and the Harvard Institute of Proteomics, a division of the medical school.

Under the agreement, Lumera and the medical school will develop a next generation silicon chip substrate that combines Lumera’s NanoCapture technology with the medical school’s methodology for nucleic acid programmable protein arrays, or NAPPA.

The collaboration is intended to result in a 10,000-spot protein array that could significantly increase the speed of drug discovery and life science research.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.